P0172Clinical relevance of a pharmacogenetic approach using multiple transporter genes to predict response and resistance to imatinib therapy in Malaysian patients with chronic myeloid leukaemia

2015 ◽  
Vol 51 ◽  
pp. e33
Author(s):  
Ravindran Ankathil ◽  
Anthony Au ◽  
Azlan Husin ◽  
Abdul Aziz Baba
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Imatinib Therapy

scholarly journals Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy

2015 ◽  
Vol 2015 ◽  
pp. 1-3 ◽  
Author(s):  
Eric K. Newcott ◽  
Abdallah A. Ellabban ◽  
Shokufeh Tavassoli ◽  
Ahmed Sallam
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Macular Oedema ◽  
Intravitreal Bevacizumab ◽  
Imatinib Therapy ◽  
Cystoid Macular Oedema ◽  
Imatinib Treatment ◽  
Intravitreal Triamcinolone ◽  
Fellow Eye

Purpose.To evaluate the efficacy of intravitreal bevacizumab and triamcinolone in the treatment of cystoid macular oedema in a case with chronic myeloid leukaemia on imatinib treatment.Methods.We treated a 78-year-old man with bilateral cystoid macular oedema with intravitreal triamcinolone and subsequent bevacizumab in one eye and intravitreal bevacizumab, alone, in the fellow eye.Results.Serial intravitreal bevacizumab with and without triamcinolone treated cystoid macular oedema in both eyes and improved the vision.Conclusion.Intravitreal bevacizumab and triamcinolone could be viable options to treat cystoid macular oedema due to chronic myeloid leukaemia and imatinib therapy.

Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

2016 ◽  
Vol 69 (9) ◽  
pp. 810-816 ◽  
Author(s):  
Eda Tanrikulu Simsek ◽  
Ahmet Emre Eskazan ◽  
Mahir Cengiz ◽  
Muhlis Cem Ar ◽  
Seda Ekizoglu ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Imatinib Therapy ◽  
Imatinib Treatment ◽  
Prognostic Impact ◽  
Bone Marrow Fibrosis ◽  
Significant Difference ◽  
Grade Ii ◽  
Marrow Fibrosis

AimsBefore the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance of MF at this new era of CML therapy.MethodsThe study cohort consisted of 135 patients with CML who were exposed to imatinib. The grades of MF pre and post imatinib together with cytogenetic and molecular responses were evaluated.ResultsSevere MF (grade II–III) was observed in 44 (33%) patients prior to imatinib therapy, and in 8 (8%) after 12 months of imatinib treatment (p=0.001). The complete cytogenetic response (CCyR) rates at 12 months did not differ according to the pre-imatinib MF grades, and CCyR rates in patients with grades 0, I, II and III MF were 36/47 (76.5%), 26/33 (78.7%), 12/23 (52.1%) and 7/10 (70%), respectively (p=0.127). There was no significant difference between patients with or without CCyR at 12 months of imatinib regarding grades of MF (p=0.785). The distribution of the major molecular response rates at 18 months according to pre-treatment grades of MF were determined as grade 0 in 38/45 (84.4%), grade I in 21/28 (75%), grade II in 14/21 (66.6%) and grade III in 7/10 (70%) (p=0.112). There was no significant difference in overall survival rates between initial MF mild (grade 0–I) and severe (grade II–III) groups (p=0.278).ConclusionsAccording to our findings, MF regresses with imatinib therapy over time, and the MF grades at diagnosis do not have a negative impact on the responses to imatinib treatment. Therefore, the adverse prognostic impact of the MF among patients with CML seems to disappear in the era of the TKIs.

Expression Dynamics Of The Immune Mediators ARG1, TBET, CIITA, IL10 AND TGFB1 IN Chronic Myeloid Leukaemia Patients During The First Year Of Imatinib Therapy

Gene ◽  
2021 ◽  
pp. 146110
Author(s):  
María Jazmín Toloza ◽  
Yesica Bestach ◽  
Marco Lincango-Yupanki ◽  
Javier Bordone ◽  
Romina Mariano ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Imatinib Therapy ◽  
First Year ◽  
Immune Mediators

scholarly journals Effectivity of imatinib therapy for the management of chronic myeloid leukemia patients

2019 ◽  
Vol 51 (1-2) ◽  
pp. 40-43
Author(s):  
Md Mokter Hossain ◽  
Mollah Obayedullah Baki ◽  
Tamanna E Nur ◽  
Zannatul Ferdous Jesmin
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Chronic Myeloid Leukaemia ◽  
Prospective Study ◽  
Myeloid Leukaemia ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Good Health ◽  
Imatinib Therapy ◽  
First Line Therapy ◽  
Line Therapy

Background: First generation tyrosine kinase inhibitor, imatinib revolutionized the treatment of chronic myeloid leukaemia, and is now the front line therapy. Imatinib provides substantial cytogenetic and molecular remission, with minimal normal hematopoiesis suppression or side effects and is now first line therapy. Objective: The aim of this prospective study was to determine the efficacy of imatinib therapy in the management of chronic myeloid leukemia in Bangladesh. Methods: This prospective study was done from June 2012 to May 2018. In this period we treated eight chronic myeloid leukaemia patients with imatinib, in Khulna division, Bangladesh. Results: Majority of the patients (50%) were in the age group of 21-30 years. Three patients died as because those patients were too poor to continue drugs. Another 5 patients were in good health and continuing follow up monthly. Among five patients, one patient have two healthy son. Conclusion: Imatinib therapy is an effective treatment regimen in the management of chronic myeloid leukaemia. The best result can be obtained if CML is dignosed earlier. Bang Med J (Khulna) 2018; 51 : 40-43

scholarly journals Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia

2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Graeme Greenfield ◽  
Ross McMullan ◽  
Nuala Robson ◽  
Julie McGimpsey ◽  
Mark Catherwood ◽  
...  
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Imatinib Therapy ◽  
Transcript Type

scholarly journals Complete haematological response to Imatinib in chronic myeloid leukaemia patients attending the Ocean Road Cancer Institute in Tanzania

2016 ◽  
Vol 18 (4) ◽  
Author(s):  
Erius Tebuka ◽  
Abel Makubi ◽  
Khamza Maunda
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Philadelphia Chromosome ◽  
Response To Therapy ◽  
Imatinib Therapy ◽  
Laboratory Findings ◽  
Haematological Response ◽  
Cell Counts ◽  
The Mean ◽  
Complete Haematological Response

Background: There is limited information on clinical characteristics, diagnosis and response to therapy of patients with chronic myeloid leukaemia (CML) in Tanzania. This hospital-based retrospective and cross-sectional study was conducted to describe the clinical and laboratory characteristics, time to diagnosis and response to first line therapy with imatinib in Philadelphia chromosome positive CML.Methods: The study was conducted at the Ocean Road Cancer Institute in Dar es Salaam, Tanzania. Participants were sequentially recruited from the outpatient clinic where a structured questionnaire was employed seeking details socio-clinical features of the disease. Haematology indices at baseline and at three months of treatment was obtained from patient’s medical records. Haematological response was determined at three months of imatinib use using leukaemia net definition.Results: Of 127 study participants, 63% were males. The mean (±standard deviation) age at diagnosis was 40 (±16) years, majority being in the third decade of life. Abdominal distention (88%) and symptoms of anaemia (84%) were the most frequent complaints. Splenomegaly (92%) and pallor (82.7%) were the common physical findings. The mean duration from consultation to diagnosis was 3(±0) weeks and mean duration from diagnosis to imatinib therapy initiation was 3 (±0.9) weeks. A total of 116 (91.3%) of patients had complete haematological response to imatinib therapy three months after therapy. There was significant decline in total white blood cell counts, basophils count, platelets and increase in haemoglobin at three months after imatinib therapy initiation.Conclusion: Majority of patients were young with clinical and laboratory findings of severe disease. Patients presented late to hospital and there was a considerable long time to reach a final diagnosis and yet haematological response was still achieved in majority of these patients with imatinib therapy. The elucidated clinical and laboratory findings should advocate early CML diagnosis and immediate referral to a tertiary hospital.

Resolution of platelet function defects with imatinib therapy in a patient with chronic myeloid leukaemia in chronic phase

2009 ◽  
Vol 20 (1) ◽  
pp. 81-83 ◽  
Author(s):  
Ashley P Ng ◽  
Patricia Servadei ◽  
Annabel Tuckfield ◽  
Anna Friedhuber ◽  
Andrew Grigg
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Platelet Function ◽  
Chronic Phase ◽  
Imatinib Therapy
Sign in / Sign up

Export Citation Format

Share Document